

Special Issue

Drug Repurposing for Cancer Therapy

Message from the Guest Editor

In this Special Issue, we propose encompassing a series of articles dealing with evidence that supports using compounds for cancer therapy that have already been approved worldwide by healthcare systems to treat other diseases or conditions. Many drugs and natural compounds used for particular purposes have shown indirect beneficial effects against cancer initiation, progression, and/or metastasis as single agents or in combination with standard chemo and/or radiotherapy. For example, the treatment of patients with metformin, originally developed for type II diabetes, has reduced the incidence of breast cancer and has led to the study of metformin as an anti-cancer agent.

Keywords

- cancer therapy
- drug repositioning
- drug repurposing
- old drugs for new uses
- new drugs
- natural compounds
- small molecules
- alternative therapies
- new indications
- multi-targeted drugs
- “off-patent” drugs

Guest Editor

Prof. Dr. Carlos M. Telleria
Experimental Pathology Unit, Department of Pathology, McGill
University, Montreal, QC H3A 2B4, Canada

Deadline for manuscript submissions

closed (20 May 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/73905

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)